Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Operating Officer | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,144 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 116,144 · Balance 116,144 F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.28 · Expires 2036-05-18 | Direct | 70,230 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 70,230 · Balance 70,230 F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.
F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 21:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 70,230 | $0.00 Strike: $15.28 | $0.00 |
DisclosureSEC source: 0002126966-26-000003 · wk-form4_1779311027.xml · derivative · entry 2 Cole Ryan · CIK 0002126966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,230 Underlying: Common Stock · 70,230 shares Expires 2036-05-18 F2 · derivative.exercise_date: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 116,144 | $0.00 | $0.00 |
DisclosureSEC source: 0002126966-26-000003 · wk-form4_1779311027.xml · nonDerivative · entry 1 Cole Ryan · CIK 0002126966 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,144 F1 · shares: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.